Intervention

Sorafenib (Nexavar, BAY43-9006)

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting0

Common conditions10

Lead sponsors shown1

Clinical trials

6 shown

An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or SorafenibNCT05594147 · 2022-10-31

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast CancerNCT01234337 · 2011-02-21

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).NCT00863746 · 2009-04-01

A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)NCT00449033 · 2007-02-01

BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)NCT00101413 · 2004-04-01

BAY43-9006 - Phase II in Advanced Breast CancerNCT00101400 · 2004-02-01

Common conditions

Breast Cancer2 Breast Neoplasms1 Cancer1 Carcinoma1 Carcinoma, Non-Small Cell Lung1 Carcinoma, Non-Small-Cell Lung1 Coronavirus Disease 2019 (COVID-19)1 Malignant Solid Tumors1 Non-Small-Cell Lung1 SARS-CoV-2 Infection1

Leading sponsors

Trial status mix

COMPLETED6

Phase mix

PHASE33

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.